Get started
Author

Ma. Ricci Gomez

Observed names: Ma. Ricci R Gomez, Ma. Ricci R. GOMEZ, Ma. Ricci R. Gomez, Ma. Ricci Resurreccion Gomez, Ma.Ricci R. Gomez
ORCID: 0000-0003-0795-8935
Observed ORCID: 0000-0003-0795-8935
OpenAlex ID: A5035239166
Rapid in-country sequencing of whole virus genomes to inform rabies elimination programmes
2020 · Kirstyn Brunker, Gurdeep Jaswant, et al. · Wellcome Open Research · 58
PDF
Lineage BA.2 dominated the Omicron SARS-CoV-2 epidemic wave in the Philippines
2022 · Yao-Tsun Li, Francisco Gerardo M Polotan, et al. · Virus Evolution · 16
PDF
From Perpetual Wetness to Soil Chemistry: Enumerating Environmental and Physicochemical Factors Favoring Oncomelania hupensis quadrasi Snail Presence in the Municipality of Gonzaga, Cagayan, Philippines
2023 · Daria L. Manalo, Jude Karlo G. Bolivar, et al. · Tropical Medicine and Infectious Disease · 9
PDF
A preliminary evaluation of a locally produced biotinylated polyclonal anti-rabies antibody for direct rapid immunohistochemical test (DRIT) in the Philippines
2020 · Daria L. Manalo, Ma.Ricci R. Gomez, et al. · Acta Tropica · 7
Immunohistochemical detection of virus antigen in the nasal planum of rabid dogs
2021 · Chun-Ho PARK, Sayaka KUBONIWA, et al. · Journal of Veterinary Medical Science · 6
PDF
FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al. · Cancer Immunology Research · 2
Comparison of the Different Brain Collection Techniques and Evaluation of Mixed Brain Tissues as a Specimen for Rabies Diagnosis
2023 · Daria Llenaresas Manalo, Ma. Ricci Resurreccion Gomez · CABI eBooks · 1
Data from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S1 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S3 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S2 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S8 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S6 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S4 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S7 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S10 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S9 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Figure S5 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Table 2 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Table 1 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Supplementary Table 3 from FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
2025 · Vikas Duhan, Ma. Ricci Gomez, et al.
Works count: 21
Citation count: 99
H-index: 5
I10-index: 2
Year
Topic
Type